Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huanxin Anshen Granules is a Traditional Chinese Medicine (TCM) formulation developed as a hospital preparation by The Second People's Hospital of Hunan Province (Hunan Provincial Brain Hospital). It is primarily indicated for the treatment of insomnia disorder and chronic sleep disturbances. The formulation is designed to "calm the spirit" and regulate psychological and behavioral mechanisms associated with sleep. In clinical research, it is often compared against or combined with cognitive behavioral therapy for insomnia (CBT-I) and conventional sedative-hypnotics like eszopiclone. Studies have also explored its impact on biological markers such as the IGF-1 gene to understand its underlying physiological effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Huanxin Anshen Granules.